Imperative Care Nets $100M for Stroke Care, Robotic Tech

Imperative Care has closed an oversubscribed $100 million convertible note financing. The round was co-led by new investors Elevage Medical Technologies and Perceptive Advisors in partnership with existing investor Catalio Capital Management, LP.

New investors Longaeva Partners LP and Brown Advisory also participated in the financing. The round was supported by Imperative Care’s existing investors, including Ally Bridge Group and Bain Capital Life Sciences.

The company also appointed Evan Melrose, MD, CEO of Elevage Medical Technologies, to its board of directors.

Imperative Care said the financing’s proceeds will support continued commercialization of its stroke and vascular thrombectomy portfolios. They will also be used for investments in next-gen and new product development, including the Telos robotic platform, as well as clinical evidence generation to show the impact of these technologies on outcomes.

“This financing is a reflection of the strong momentum we have built and the confidence our investors—new and existing—have in our vision,” said Fred Khosravi, chairman and CEO of Imperative Care. “We are expanding access to life-saving technologies for patients at the most critical moments of their lives, and this capital positions us to continue driving forward on that mission across stroke, vascular, and beyond.”

In January, the company launched and announced the first patient cases with its new Zoom 4S catheter, an advanced aspiration thrombectomy device for ischemic stroke treatment.